Medivir AB (LTS:0GP7)
kr 2.73 -0.19669 (-6.72%) Market Cap: 302.85 Mil Enterprise Value: 146.87 Mil PE Ratio: 0 PB Ratio: 1.94 GF Score: 58/100

Medivir AB at Redeye Fight Cancer Day (Virtual) Transcript

Jan 19, 2023 / 12:35PM GMT
Release Date Price: kr7.92
Richard Ramanius
Redeye AB - Analyst

Now we welcome Jens Lindberg from Medivir. Please go ahead with your presentation.

Jens Lindberg
Medivir AB - CEO

Thank you, Richard. And okay. So let's move forward. Important slide, lot of important information, you can access it on our website for further information, sort of intro for Medivir for those of you who don't know. Today, we focus on two areas and there is our lead project where we have our top priority, which is for structures like fostroxacitabine or we call it fostrox, which is in development for liver cancer, which we drive ourselves.

And I would say we spent around sort of 80% of our time on that project. Then we have a few additional assets that we have for out-licensing, both in the area of oncology, but also outside. But where we try to create value together with our partners. For the presentation today, I will focus on our lead project, but I will touch upon a few of the other projects towards the end.

So if you go into fostrox in sort of a short overview, if you look at it in

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot